First Indian Rate Contract Kicks Off in 2017

India, New Delhi- On January 4, MicroPort Scientific India Private Limited ("MicroPort® Scientific India"), the Indian subsidiary of MicroPort Scientific Corporation ("MicroPort® Scientific"), announced that it successfully got the first annual rate contract for its innovative Firehawk® Rapamycin Target Eluting Coronary Stent System ("Firehawk®") from Sree Chitra Tirunal Institute for Medical Sciences and Technology, Trivandrum, an Institute of National Importance under the Department of Science and Technology, Government of India.
 
Sree Chitra Tirunal Institute for Medical Sciences and Technology, Trivandrum is a prestigious Indian government hospital that offers advanced treatment using modern technologies in several specialized areas such as interventional radiology, cardiac electrophysiology, deep brain stimulation for movement disorders, epilepsy surgery, pediatric cardiac surgery, base of skull and vascular surgeries, to name a few. The institute has excellent facilities and teams of professionals dedicated to the development of innovative biomedical devices and products, evaluation of medical devices to global specifications, training in novel medical specialties and research in medical and public health areas of social relevance.
 
Founded on August 11, 2016, the Indian subsidiary aims to serve the Indian patients with high-quality research-based medical solutions at affordable prices. Its first Indian rate contract means the innovative product Firehawk™ was recognized by Indian experts and will earn a place in the India market.
 
"India is one of the most important strategic markets for MicroPort® Scientific, and we are extremely pleased to see our star product Firehawk® recognized by local experts," said Dr. Linda Lin, Vice President of International Business. "By constant endeavor of the whole team, we believe our products will benefit more overseas patients."
 
Mr. Riyaz Desai, Managing Director of MicroPort® Scientific India, said: "As a new member of MicroPort® Scientific, the Indian subsidiary aims to serve the Indian patients with high-quality research-based medical solutions at affordable prices. MicroPort® is committed to save and reshape many lives and improve quality of life of Indian patients. This first rate contract from a prestigious Indian government hospital signifies an auspicious start of business development of MicroPort in Indian market".
 
India has the third largest amount of PCI cases in the world, and the market is experiencing rapid development in recent years. The first rate contract from a famous local government hospital marks a good beginning of market expansion of MicroPort® Scientific in India, to bring more ideal solutions to Indian patients who suffer from cardiovascular diseases.